Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”),
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update | BioSpace
   - Reported positive topline results from ENTRIGUE Phase 2
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
   - Reported positive topline results from ENTRIGUE Phase 2
Nautilus, Inc. Reports Fiscal First Quarter 2023 Results
VANCOUVER, Wash.--(BUSINESS WIRE)--Aug 9, 2022--Nautilus, Inc. (NYSE: NLS) today reported
Nautilus, Inc. Reports Fiscal First Quarter 2023 Results
VANCOUVER, Wash.--(BUSINESS WIRE)--Nautilus, Inc. (NYSE: NLS) today reported its unaudited
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc.First two RAS(ON) Inhibitor drug candidates advance into
Blueprint Medicines Reports Second Quarter 2022 Results
-- Achieved $36.5 million in total revenues, including $28.5 million